delivery altace

The hope study was a large, multicenter, randomized, double-blind, placebo-controlled, 2 x 2 factorial design study conducted in 9541 patients 4645 on altace who were 55 years or older and considered at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that was accompanied by at least one other cardiovascular risk factor hypertension, elevated total cholesterol levels, low hdl levels, cigarette smoking, or documented microalbuminuria .
Continue reading